"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial looking at atezolizumab and cabozantinib for non small cell lung cancer that has spread (CONTACT 01)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is comparing atezolizumab and cabozantinib with docetaxel for people with non small cell lung cancer.
It is for people whose cancer has spread elsewhere in the body. This is advanced lung cancer.
More about this trial
Doctors are looking for ways to improve treatment for people with advanced non small cell lung cancer (NSCLC).
In this trial they are looking at a new combination of drugs. This includes 2 drugs called atezolizumab and cabozantinib.
Atezolizumab is a drug you may have to treat advanced NSCLC that has got worse. It is an immunotherapy. It helps the
Cabozantinib is a type of cancer growth blocker. It stops signals that cancer cells use to divide and grow. It is a new drug for lung cancer. Researchers want to find out if adding it to atezolizumab slows cancer growth.
Docetaxel is a chemotherapy drug. It is a usual treatment for NSCLC that has spread.
In this trial some people have atezolizumab and cabozantinib. And some people have docetaxel.
The main aims of the trial are to:
- find out how safe it is to have atezolizumab and cabozantinib together
- find how well this combination of treatment works compared to docetaxel
- learn more about the side effects
Who can enter
The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply. You:
- have NSCLC that has spread elsewhere in the body
- have cancer that got worse during or after having an
immunotherapyand chemotherapy that included a platinum drug. The team check which treatments you had and when you had them to see if you are suitable for the trial
- have an area of cancer the doctor can see and measure on a scan
- have a sample of tissue available for the trial team to do some tests on or you are willing to give a new sample
- are well enough to carry out all your normal activities but you might not be able to do heavy physical work (performance status of 0 or 1)
- have satisfactory blood test results
- are willing to use reliable contraception during the trial and for a period of time afterwards if there is a chance you or your partner could become pregnant
- are at least 18 years old
Who can’t take part
You cannot join this trial if any of these apply. You:
- have cancer that has spread to the brain and spinal cord unless it isn’t causing symptoms, has been treated and is stable
- have any other cancer or had another cancer in the last 3 years that needs treatment apart from
non melanoma skin cancer, prostate canceror carcinoma (CIS) of the prostate, cervix or breast that has been successfully treated
- have lung cancer with the EGFR or ALK gene change
- have had cabozantinib, docetaxel or another similar drug in the past
- have had an experimental drug in the last 28 days
- have pain caused by cancer that isn’t well controlled with medication
- have side effects from past treatments that aren’t getting better apart from hair loss or moderate numbness and tingling in your hands and feet
You can’t join the trial if the following apply. You:
- have areas of fluid on the lung, heart or tummy that need frequent draining
- have severe liver damage
- have had a serious heart problem including a heart attack or a stroke within the last 6 months, you have an abnormal heart rhythm or another heart condition that needs treatment. The trial team check if you have a heart condition before you join the trial
- have had major surgery in the last 4 weeks or need to have major surgery soon
- have an
autoimmune diseaseunless it is type 1 diabetes, hair loss (alopecia), thyroid problems that are controlled by medications or certain skin conditions that don’t need treatment
- have scarring on the lungs or active inflammation of the lungs (
- have had a
stem cell transplantor an organ transplant
- have had treatment to stimulate the
immune systemsuch as interferon in the last 2 weeks or this treatment hasn’t completely cleared your body
- have had treatment that damps down the immune system such as steroids within 2 weeks of starting trial treatments unless it was a low dose
- are taking drugs such as warfarin to thin your blood
- have had a blood clot in your leg or lung within 6 months of starting trial treatment
- have high blood pressure that isn’t well controlled with medication
- have problems with your
digestive systemsuch as areas of cancer, inflammatory bowel disease or a blocked bowel
- have areas of cancer that have grown into the blood vessels in the lungs
- have an increased risk of having a bleed or you had a big bleed in the last 3 months
- have a serious wound, ulcer or bone fracture that isn’t getting better
- have a problem absorbing nutrients
- have a lesion in the lung called a cavitating lesion or cancer in your airways causing breathing difficulties
- have a problem with your kidneys and need to have dialysis
- have HIV, an active hepatitis B or hepatitis C infection, tuberculosis (TB) or a recent severe infection that needed treatment
- can’t swallow tablets
You can’t take part if the following apply. You:
- have had a severe allergic reaction to atezolizumab, cabozantinib or docetaxel or anything they contain
- have had a
live vaccinein the last 4 weeks or might need one during the trial
- are pregnant or breastfeeding
This is a phase 3 trial. It is taking place worldwide. The researchers need 350 people to take part including at least 15 from the UK.
It is randomised trial. You are put into a group by a computer. Neither you nor your doctor will be able to decide which group you are in. There are 2 treatment groups. You have 1 of the following:
- atezolizumab and cabozantinib
You have treatment for as long as it is working and the side effects aren’t too bad.
Atezolizumab and cabozantinib
You have atezolizumab as a drip into a vein. You have it once every 3 weeks.
Cabozantinib is a tablet. You take them once a day, every day.
You have docetaxel as a drip into a vein. You have it once every 3 weeks.
Blood and tissue samples
The researchers ask you to give an extra tissue sample. They also ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.
The researchers use the samples to look for differences in substances called
You need to agree to give most of the samples in the trial. There are a few you don’t need to agree to if you don’t want to. The team can let you know more about this.
You see a doctor and have some tests before you can take part in the trial. These include:
You may also need to give a tissue sample (
During treatment you see the doctor every 3 weeks for a check up and blood tests.
You have a CT or MRI scan:
- every 6 weeks in the first year and then
- every 9 weeks until your cancer gets worse
When you finish treatment you see the doctor 1 month later. If your cancer hasn’t got worse you continue to have scans every 6 to 9 weeks. You have a final scan after about 6 weeks if your cancer gets worse.
The team follow you up every 3 months when you finish treatment. You might see them at a routine hospital appointment or they may call you to see how you are getting on.
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Atezolizumab can affect the immune system. It may cause inflammation in different parts of the body which can cause serious side effects. They could happen during treatment, or some months after treatment has finished. Rarely, these side effects could be life threatening.
If you have any of these side effects, you should tell the doctor or nurse as soon as possible. You should tell them you are on or have been on an immunotherapy.
The most common side effects of atezolizumab are:
- tiredness (fatigue) or lack of energy
- joint, muscle or bone pain
- loss of appetite
- shortness of breath
- urine infections
- skin rash or itchy skin
- feeling or being sick
The most common side effects of cabozantinib include:
- tummy (abdominal) pain
- changes to how the
- blisters, rash, or pain on the hands or feet
- skin rash
- changes to how the liver works
- changes to your voice
- taste changes, loss of appetite or weight loss
- tiredness (fatigue)
- constipation or diarrhoea
- hair colour changes or hair loss
- high blood pressure
- inflammation of the tissues that line the inside of the body (mucous membranes)
- mouth and throat sores or swelling
- feeling or being sick
We have information about the side effects of:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Tom Newsom-Davis
Chugai Pharmaceutical Co Ltd
F. Hoffmann La Roche
Ipsen Pharma SAS
Takeda Pharmaceutical Co Ltd